Ocular Pain - Pipeline Insight, 2024

This Ocular Pain - Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Ocular Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Ocular Pain Understanding

Ocular Pain: Overview

Ocular neuropathic pain is a diagnosis of exclusion which refers to the heightened perception of pain in response to normally non-painful stimuli. It usually presents without any visible objective exam findings, making it extremely difficult to identify. For this reason, it is often misdiagnosed as dry eye disease. This activity describes the etiology, epidemiology, evaluation, treatment, and management of ocular neuropathic pain. Ocular neuropathic pain is an important differential to consider because many patients get misdiagnosed due to its significant overlap with dry eye disease. The disparity between signs and symptoms often results in patients being dismissed or considered malingering, hysterical, or psychosomatic.

Ocular Pain - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Pain pipeline landscape is provided which includes the disease overview and Ocular Pain treatment guidelines. The assessment part of the report embraces, in depth Ocular Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Pain R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Pain.

This segment of the Ocular Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ocular Pain Drugs
APP13007: Formosa Pharmaceuticals APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel formulation of the potent corticosteroid, clobetasol propionate, for the treatment of inflammation and pain after cataract surgery. APP13007 was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration.

Ok-201: OKYO Pharma OK-201, a lipidated cyclized bovine adrenal medulla (“BAM8”) analogue, a promising candidate for the treatment of neuropathic and inflammatory pain, was licensed from Tuffs University on February 21, 2018. OK-201 is designed to activate a human MAS-related G protein-coupled receptor, or MRGPR, which is a promising analgesic target. This receptor is expressed mainly in sensory neurons and is involved in the perception of pain. Activation of MRGPR by BAM8 peptides inhibits pain by modulating Ca2+ influx.

Ocular Pain: Therapeutic Assessment

This segment of the report provides insights about the Ocular Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ocular Pain

There are approx. 12+ key companies which are developing the therapies for Ocular Pain. The companies which have their Ocular Pain drug candidates in the most advanced stage, i.e. Phase II include Formosa Pharmaceuticals.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Ocular Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ocular Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Pain drugs.

Ocular Pain Report Insights

• Ocular Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ocular Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ocular Pain drugs?
• How many Ocular Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ocular Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ocular Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pharmaleads
• Vyluma
• Novaliq
• Sun Pharma Advanced Research Company
• Formosa Pharmaceuticals
• On Target Therapeutics
• Sylentis
• Surface Ophthalmics
• Reata Pharmaceuticals
• Ocular Therapeutix
• OKYO Pharma

Key Products

• PL265
• NVK032
• EyeSol
• SDN 037
• APP13007
• OK 101
• Tivanisiran
• Betamethasone ophthalmic
• Omaveloxolone
• PL 37
• Bupivacaine ophthalmic insert
• OK-201

This product will be delivered within 1-3 business days.